Elekta announces strategic partnership with McLaren Health Care to improve cancer care in Michigan

Agreement secures full Elekta solution across the McLaren enterprise
STOCKHOLM, December 18, 2013 – The ability to effectively manage data across
disparate health systems to help drive quality care will be a cornerstone for
health systems of the future. Elekta is proud to announce today that it has
joined forces with Michigan-based McLaren Health Care to launch MOSAIQ® oncology
information system throughout McLaren’s cancer network. This partnership will
enable McLaren to deploy MOSAIQ to centralize patient information across
radiation oncology, particle therapy and medical oncology into a single user
interface, accessible by multi-disciplinary teams across McLaren’s multiple
locations.

“By developing a long-term agreement with McLaren, Elekta reinforces its
leadership in oncology information systems,” explained Tomas Puusepp, President
and CEO of Elekta. “Our collaboration with McLaren will further strengthen the
integration of the entire cancer system to help improve patient care,” Puusepp
added.

The agreement entered today goes beyond MOSAIQ; it currently includes 15 Elekta
linear accelerators, one Leksell Gamma Knife®, seven brachytherapy systems, and
Monaco® treatment planning system to further drive improvements in quality and
patient safety. The agreement will be booked in Elekta’s second half of fiscal
year 2013-14 and is valued at more than USD 50 million.

“At McLaren we are committed to delivering the best cancer care in the world.
Today, McLaren is one of the largest oncology providers in the State of Michigan
and one of the largest in the United States,” said Philip A. Incarnati,
President and Chief Executive Officer of McLaren Health Care. “We knew we needed
a global leader to help us connect our facilities in a way that allows providers
to function in a multi-disciplinary fashion. Elekta is that partner,” he
explained.

McLaren will move to replace its current linear accelerator fleet with Elekta
Versa HD™, a single system that delivers high-volume conventional techniques in
addition to advanced treatments that require precise targeting. Versa HD is
equipped with the Agility™ 160-leaf multileaf collimator for high-speed, high
-precision beam shaping to support extremely accurate tumor targeting and to
maximize the preservation of healthy tissue.

“By choosing Elekta as our partner, we will be able to give our patients access
to the most advanced technology for treating cancer,” said Justin Klamerus, MD,
MMM, Chief Quality Officer and lead for McLaren’s community-based cancer
programs. “The comprehensive solution provided by Elekta, along with McLaren’s
slated opening of the Proton Therapy Center in Flint, enables our cancer program
to become one of the most advanced radiation oncology providers in the world,”
highlighted Klamerus. “We have spent 18 months exploring this partnership and we
are confident that Elekta will help us transform cancer care for our patients.
No mission is greater than this,” he added.

# # #

For further information, please contact:
Johan Andersson, Director, Investor Relations, Elekta AB
Tel: +46 702 100 451, e-mail: johan.andersson@elekta.com
Time zone: CET: Central European Time

Michelle Joiner, Director, Global Public Relations and Brand Management, Elekta
Tel: +1 770-670-2447, e-mail: michelle.joiner@elekta.com
Time zone: ET: Eastern Time

The above information is such that Elekta AB (publ) shall make public in
accordance with the Securities Market Act and/or the Financial Instruments
Trading Act. The information was published at 07:30 CET on December 18, 2013.

About Elekta
Elekta is a human care company pioneering significant innovations and clinical
solutions for treating cancer and brain disorders. The company develops
sophisticated, state-of-the-art tools and treatment planning systems for
radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing
software systems across the spectrum of cancer care. Stretching the boundaries
of science and technology, providing intelligent and resource-efficient
solutions that offer confidence to both health care providers and patients,
Elekta aims to improve, prolong and even save patient lives.

Today, Elekta solutions in oncology and neurosurgery are used in over 6,000
hospitals worldwide. Elekta employs around 3,500 employees globally. The
corporate headquarters is located in Stockholm, Sweden, and the company is
listed on the Nordic Exchange under the ticker STO: EKTAB. Website:
www.elekta.com.

About McLaren Health Care
McLaren Health Care, a 501(c)3 nonprofit organization, is a large, clinically
integrated health delivery system that includes 11 hospitals, ambulatory surgery
centers, imaging centers, the state’s only proton therapy center, the state’s
largest network of cancer centers and providers, an employed primary care
physician network, assisted living facilities, commercial and Medicaid HMOs,
home health care and hospice, durable medical equipment, retail pharmacy
services, and a wholly-owned medical malpractice insurance company. McLaren’s
current cancer care delivery network has 16 locations, treating in excess of
12,000 of Michigan’s 57,500 newly diagnosed cancer cases. McLaren’s network
includes an NCI-designated comprehensive cancer center. More information at
www.mclaren.org.